TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04257578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Given IV
Study: NCT04377139

Intervention type: PROCEDURE
Intervention: Prophylaxis
Description: The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR

Intervention type: PROCEDURE
Intervention: Preemptive
Description: The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
Study: NCT01634204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KiloCoach
Description: Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months.
Study: NCT03473145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coaching
Description: Health Coaching sessions will be aimed at goal setting, implementing strategies, overcoming barriers, \& relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Health Coaching sessions will be aimed at goal setting, implementing strategies, overcoming barriers, \& relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Health Coaching sessions will be aimed at goal setting, implementing strategies, overcoming barriers, \& relapse prevention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: activPAL inclinometer
Description: Participants in the intervention study arms (B \& C) will wear the ActivPAL device for the first 4 weeks of the program and then again in weeks 8 and 9. The device will monitor their sitting and standing time and will allow Health Coaches to provide feedback and will assist the participant in developing an action plan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: activPAL inclinometer
Description: Participants in the intervention study arms (B \& C) will wear the ActivPAL device for the first 4 weeks of the program and then again in weeks 8 and 9. The device will monitor their sitting and standing time and will allow Health Coaches to provide feedback and will assist the participant in developing an action plan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.
Description: Participants in the intervention study arms (B \& C) will receive tools to prompt standing or sit-to-stand transitions such as wearable wrist devices, standing desks or tables (Group B only), mechanical and/or electronic timers, or access to mobile apps or computer programs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.
Description: Participants in the intervention study arms (B \& C) will receive tools to prompt standing or sit-to-stand transitions such as wearable wrist devices, standing desks or tables (Group B only), mechanical and/or electronic timers, or access to mobile apps or computer programs.
Study: NCT03152812

Intervention type: PROCEDURE
Intervention: plantar surface reconstruction by free flaps
Description: use of free skin or free muscle flaps for reconstruction of plantar surface

Intervention type: PROCEDURE
Intervention: plantar surface reconstruction by free flaps
Description: use of free skin or free muscle flaps for reconstruction of plantar surface
Study: NCT02685774

Intervention type: DRUG
Group type: OTHER
Intervention: Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg
Description: Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg
Description: Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
Study: NCT02944682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) cookstove
Description: The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
Study: NCT01935557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous heparin infusion
Description: continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent heparin infusion
Description: Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
Study: NCT03676816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginal self sampling
Description: This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: provider-performed endocervical sampling
Description: provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
Study: NCT03114527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Orally bioavailable, highly selective small molecule inhibitor of CDK4/6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Orally bioavailable, highly selective small molecule inhibitor of CDK4/6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibitor
Study: NCT02685774

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-395 0.25/500mg
Description: CKD-395 0.25/500mg 2T oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-395 0.25/500mg
Description: CKD-395 0.25/500mg 2T oral administration
Study: NCT03114527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibitor
Study: NCT01608048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation (TEAS);EA
Description: TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
Study: NCT00949780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloral Hydrate
Study: NCT01534468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza Subvirion Vaccine, H7N7
Description: At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza Subvirion Vaccine, H7N7
Description: At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza Subvirion Vaccine, H7N7
Description: At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza Subvirion Vaccine, H7N7
Description: At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
Study: NCT00298896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-595
Study: NCT02880371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-382
Description: ARRAY-382 will be taken by mouth once daily at a fixed dose.
Study: NCT03908229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trainee colonoscopy
Description: Colonoscopy performed by trainee
Study: NCT02880371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-382
Description: ARRAY-382 will be taken by mouth once daily at a fixed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
Study: NCT04403295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Specialty Care
Description: In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-consultation
Description: In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
Study: NCT02912481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior tibial artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dorsalis pedis artery
Study: NCT01086579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)
Description: Coronary Artery Bypass Graft (CABG)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus (Paclitaxel eluting stent)
Description: Percutaneous transluminal coronary angioplasty (PTCA) with stent
Study: NCT04693364

Intervention type: OTHER
Intervention: Decision Aid
Description: Use 3D printed breast model

Intervention type: PROCEDURE
Intervention: Discussion
Description: Participate in consultation

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT03079258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
Study: NCT01663272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABOZANTINIB
Description: Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
Study: NCT01787513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBM
Description: CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CBM
Description: CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCBT
Description: iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: iCBT
Description: iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
Study: NCT03275727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iACT-BC
Description: A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: iACT-BC
Description: A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
Study: NCT03908229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Experienced physician colonoscopy
Description: Experienced physician colonoscopy
Study: NCT01327989

Intervention type: DEVICE
Intervention: Solitaire™ FR device
Description: Mechanical Thrombectomy
Study: NCT00310869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Developmental Care in the NICU
Description: Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
Study: NCT01912391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Selegiline)
Description: Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
Study: NCT02355366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused Therapy
Description: Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Educational Treatment
Description: Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
Study: NCT01438346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Abuse Education
Description: 10 weeks of usual care for substance abuse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body Bridging
Description: Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
Study: NCT02317302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG-PET/MR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Study: NCT03991741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes
Description: Autologous TILs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes
Description: Autologous TILs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Interleukin 2
Description: 720,000 IU/kg every 8 hours for up to 15 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Interleukin 2
Description: 720,000 IU/kg every 8 hours for up to 15 doses
Study: NCT01922310

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Communication intervention
Description: The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours.
Study: NCT02984176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone Tab 40 mg
Description: 3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: 3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
Study: NCT02845037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
Study: NCT00699881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
Study: NCT04418206

Intervention type: OTHER
Group type: OTHER
Intervention: patients COVID 19
Description: Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
Study: NCT04375423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment and intervention: Behaviorally-dependent messaging
Description: In response to behavioral data submitted intervention arm participants receive messages on their phones reinforcing healthy behaviors or encouraging alternative behaviors to limit risks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ecological momentary assessment only
Description: Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment only
Description: Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
Study: NCT03713489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet
Description: Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
Study: NCT00127790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Insomnia (CBT-I)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Insomnia (CBT-I)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Pain (CBT-P)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Pain (CBT-P)
Study: NCT01340989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alteration of the insufflation gas
Description: addition of 4% oxygen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full conditioning
Description: addition of 4% oxygen + 10% nitrous oxide to the peritoneum~* humidification~* set temperature of 32°C

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pneumoperitoneum
Description: no intervention besides the use of CO2
Study: NCT04543422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: Green tea extract capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing inert material.
Study: NCT00287911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Some patients may also undergo brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
Study: NCT04101526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference
Description: Six sessions of Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference. Sessions address topics such as sleep education, sleep hygiene, sleep restriction, stimulus control, relapse prevention, and cognitive restructuring.